SCHEMBL16148359

SCHEMBL16148359

N[C@@H](CCc1ccccc1F)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A5 Q15758 3/20 0.53
TAAR1 Q96RJ0 1/20 0.50
PTPN1 P18031 1/20 0.50
KIF11 P52732 4/20 0.47
ALPI P09923 1/20 0.46
PKM P14618 1/20 0.46
PTGS1 P23219 1/20 0.46
XIAP P98170 1/20 0.46
SLC7A5 Q01650 1/20 0.46
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
GRIK1 P39086 2/20 0.43
GRIA1 P42261 1/20 0.43
GRIA2 P42262 1/20 0.43
GRIA3 P42263 1/20 0.43
GRIA4 P48058 1/20 0.43
GRIK2 Q13002 1/20 0.43
GRIK3 Q13003 1/20 0.43
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31691522 1.00 SLC1A5 (0.53) SLC1A5TAAR1PTPN1KIF11ALPI
SCHEMBL16148360 1.00 SLC1A5 (0.53) SLC1A5TAAR1PTPN1KIF11ALPI
SCHEMBL22444963 1.00 SLC1A5 (0.53) SLC1A5TAAR1PTPN1KIF11ALPI
SCHEMBL428267 0.90 SLC1A5 (0.51) SLC1A5TAAR1PTPN1KIF11ALPI
SCHEMBL3592508 0.84 TAAR1 (0.50) TAAR1PPARGPPARA
SCHEMBL7303381 0.83 KMT2A (0.54) SLC1A5
SCHEMBL27254720 0.82 SLC1A5 (0.48) SLC1A5TAAR1PTPN1KIF11
SCHEMBL29401250 0.82 PKM (0.58) SLC1A5PTPN1ALPIPKMPTGS1
SCHEMBL268942 0.82 PKM (0.58) SLC1A5PTPN1ALPIPKMPTGS1
SCHEMBL44127 0.82 PKM (0.58) SLC1A5PTPN1ALPIPKMPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10344060-B2 Potent and selective inhibitors of Nav1.7 AMGEN INC. (US) 2019-07-09 US disclosed
EP-2970408-B1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 AMGEN INC (US) 2018-01-10 EP disclosed
US-20160024159-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 AMGEN INC. (US) 2016-01-28 US disclosed
EP-2970408-A2 POTENT AND SELECTIVE INHIBITORS OF Nav1.7 Amgen Inc. (US) 2016-01-20 EP disclosed
WO-2014165277-A2 POTENT AND SELECTIVE INHIBITORS OF Nav1.7 AMGEN INC. (US) 2014-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344060-B2 Potent and selective inhibitors of Nav1.7 SCN7A, SCN9A, SCN1A SLC1A5 1893/4885TAAR1 2165/4885PTPN1 1292/4885
US-20160024159-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 SCN7A, SCN9A, SCN1A SLC1A5 1893/4885TAAR1 2165/4885PTPN1 1292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.